RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase

Scott A. Wadsworth, Druie E. Cavender, Scott A. Beers, Praful Lalan, Peter H. Schafer, Elizabeth A. Malloy, Wei Wu, Bohumila Fahmy, Gilbert C. Olini, Janet E. Davis, J. Lee Pellegrino-Gensey, Michael P. Wachter, John Siekierka

Research output: Contribution to journalArticleResearchpeer-review

148 Citations (Scopus)

Abstract

Tumor necrosis factor-α (TNF-α), a cytokine secreted by activated monocytes/macrophages and T lymphocytes, has been implicated in several disease states, including rheumatoid arthritis, inflammatory bowel disease, septic shock, and osteoporosis. Monocyte/macrophage production of TNF-α is dependent on the mitogen-activated protein kinase p38. RWJ 67657 (4-[4-(4- fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1- ol) inhibited the release of TNF-α by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC50 value of 13 nM. This compound was approximately 10- fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested. RWJ 67657 inhibited the enzymatic activity of recombinant p38α and β, but not γ, or δ, in vitro and had no significant activity against a variety of other enzymes. In contrast, SB 203580 significantly inhibited the tyrosine kinases p56 lck and c-src (IC50 = 5 μM). RWJ 67657 did not inhibit T cell production of interleukin-2 or interferon-γ, and did not inhibit T cell proliferation in response to mitogens. RWJ 67657 inhibited TNF-α production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. Based on these favorable biological properties, RWJ 67657 may have use as a treatment for inflammatory diseases.

Original languageEnglish
Pages (from-to)680-687
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume291
Issue number2
StatePublished - 1 Nov 1999

Fingerprint

p38 Mitogen-Activated Protein Kinases
Tumor Necrosis Factor-alpha
Inhibitory Concentration 50
T-Lymphocytes
Monocytes
Lipopolysaccharides
Blood Cells
Macrophages
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
Superantigens
Septic Shock
Mitogens
Inflammatory Bowel Diseases
Protein-Tyrosine Kinases
Interferons
Osteoporosis
Interleukin-2
Oral Administration
RWJ 67657
Rheumatoid Arthritis

Cite this

Wadsworth, S. A., Cavender, D. E., Beers, S. A., Lalan, P., Schafer, P. H., Malloy, E. A., ... Siekierka, J. (1999). RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Journal of Pharmacology and Experimental Therapeutics, 291(2), 680-687.
Wadsworth, Scott A. ; Cavender, Druie E. ; Beers, Scott A. ; Lalan, Praful ; Schafer, Peter H. ; Malloy, Elizabeth A. ; Wu, Wei ; Fahmy, Bohumila ; Olini, Gilbert C. ; Davis, Janet E. ; Pellegrino-Gensey, J. Lee ; Wachter, Michael P. ; Siekierka, John. / RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. In: Journal of Pharmacology and Experimental Therapeutics. 1999 ; Vol. 291, No. 2. pp. 680-687.
@article{9e4bc1619938448a88f408b385ba528a,
title = "RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase",
abstract = "Tumor necrosis factor-α (TNF-α), a cytokine secreted by activated monocytes/macrophages and T lymphocytes, has been implicated in several disease states, including rheumatoid arthritis, inflammatory bowel disease, septic shock, and osteoporosis. Monocyte/macrophage production of TNF-α is dependent on the mitogen-activated protein kinase p38. RWJ 67657 (4-[4-(4- fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1- ol) inhibited the release of TNF-α by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC50 value of 13 nM. This compound was approximately 10- fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested. RWJ 67657 inhibited the enzymatic activity of recombinant p38α and β, but not γ, or δ, in vitro and had no significant activity against a variety of other enzymes. In contrast, SB 203580 significantly inhibited the tyrosine kinases p56 lck and c-src (IC50 = 5 μM). RWJ 67657 did not inhibit T cell production of interleukin-2 or interferon-γ, and did not inhibit T cell proliferation in response to mitogens. RWJ 67657 inhibited TNF-α production in lipopolysaccharide-injected mice (87{\%} inhibition at 50 mg/kg) and in rats (91{\%} inhibition at 25 mg/kg) after oral administration. Based on these favorable biological properties, RWJ 67657 may have use as a treatment for inflammatory diseases.",
author = "Wadsworth, {Scott A.} and Cavender, {Druie E.} and Beers, {Scott A.} and Praful Lalan and Schafer, {Peter H.} and Malloy, {Elizabeth A.} and Wei Wu and Bohumila Fahmy and Olini, {Gilbert C.} and Davis, {Janet E.} and Pellegrino-Gensey, {J. Lee} and Wachter, {Michael P.} and John Siekierka",
year = "1999",
month = "11",
day = "1",
language = "English",
volume = "291",
pages = "680--687",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

Wadsworth, SA, Cavender, DE, Beers, SA, Lalan, P, Schafer, PH, Malloy, EA, Wu, W, Fahmy, B, Olini, GC, Davis, JE, Pellegrino-Gensey, JL, Wachter, MP & Siekierka, J 1999, 'RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase', Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 2, pp. 680-687.

RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. / Wadsworth, Scott A.; Cavender, Druie E.; Beers, Scott A.; Lalan, Praful; Schafer, Peter H.; Malloy, Elizabeth A.; Wu, Wei; Fahmy, Bohumila; Olini, Gilbert C.; Davis, Janet E.; Pellegrino-Gensey, J. Lee; Wachter, Michael P.; Siekierka, John.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 291, No. 2, 01.11.1999, p. 680-687.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase

AU - Wadsworth, Scott A.

AU - Cavender, Druie E.

AU - Beers, Scott A.

AU - Lalan, Praful

AU - Schafer, Peter H.

AU - Malloy, Elizabeth A.

AU - Wu, Wei

AU - Fahmy, Bohumila

AU - Olini, Gilbert C.

AU - Davis, Janet E.

AU - Pellegrino-Gensey, J. Lee

AU - Wachter, Michael P.

AU - Siekierka, John

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Tumor necrosis factor-α (TNF-α), a cytokine secreted by activated monocytes/macrophages and T lymphocytes, has been implicated in several disease states, including rheumatoid arthritis, inflammatory bowel disease, septic shock, and osteoporosis. Monocyte/macrophage production of TNF-α is dependent on the mitogen-activated protein kinase p38. RWJ 67657 (4-[4-(4- fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1- ol) inhibited the release of TNF-α by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC50 value of 13 nM. This compound was approximately 10- fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested. RWJ 67657 inhibited the enzymatic activity of recombinant p38α and β, but not γ, or δ, in vitro and had no significant activity against a variety of other enzymes. In contrast, SB 203580 significantly inhibited the tyrosine kinases p56 lck and c-src (IC50 = 5 μM). RWJ 67657 did not inhibit T cell production of interleukin-2 or interferon-γ, and did not inhibit T cell proliferation in response to mitogens. RWJ 67657 inhibited TNF-α production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. Based on these favorable biological properties, RWJ 67657 may have use as a treatment for inflammatory diseases.

AB - Tumor necrosis factor-α (TNF-α), a cytokine secreted by activated monocytes/macrophages and T lymphocytes, has been implicated in several disease states, including rheumatoid arthritis, inflammatory bowel disease, septic shock, and osteoporosis. Monocyte/macrophage production of TNF-α is dependent on the mitogen-activated protein kinase p38. RWJ 67657 (4-[4-(4- fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1- ol) inhibited the release of TNF-α by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC50 value of 13 nM. This compound was approximately 10- fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested. RWJ 67657 inhibited the enzymatic activity of recombinant p38α and β, but not γ, or δ, in vitro and had no significant activity against a variety of other enzymes. In contrast, SB 203580 significantly inhibited the tyrosine kinases p56 lck and c-src (IC50 = 5 μM). RWJ 67657 did not inhibit T cell production of interleukin-2 or interferon-γ, and did not inhibit T cell proliferation in response to mitogens. RWJ 67657 inhibited TNF-α production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. Based on these favorable biological properties, RWJ 67657 may have use as a treatment for inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=0032745423&partnerID=8YFLogxK

M3 - Article

VL - 291

SP - 680

EP - 687

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -

Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Journal of Pharmacology and Experimental Therapeutics. 1999 Nov 1;291(2):680-687.